Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Major Amendment - Wilate, August 2, 2007

Our STN: BL 125251/0

Octapharma Pharmazeutika Produktionsges. m.b.H
Attention: Barbara Rangetiner, Ph.D.
Oberlaaer Strasse 235
A-1100 Vienna

Dear Dr. Rangetiner:

We received your 23-JUL-2007 amendment to your biologics license application (BLA) submitted under section 351 of the Public Health Service Act for Von Willebrand Factor Concentrate (Human) on 25-JUL-2007.

We consider your submission a major amendment under the Prescription Drug User Fee Act of 1992.

Because we received this major amendment within three months of the action due date on this application we will add an additional three months to the time by which we should complete our review. Therefore, the goal date is 13-JAN-2008.

If you have any questions, please contact Mr. Franklin T. Stephenson, at (301) 827-6165.

Sincerely yours,

Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics
Evaluation and Research

Page Last Updated: 09/23/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English